Targeted cancer drug market set to reach $51 billion by 2015, led by Pfizer; barriers to use of oral cancer drugs identified

The targeted cancer drug market will double in value, from $25 billion in 2008 to $51 billion in 2015, according to new research from Decision Resources. Growth will be driven by increasing sales of existing marketed targeted agents and by sales of new targeted agents introduced to the market prior to the end of 2015, it notes.

In 2008, the major players in the targeted cancer therapies market were led by Roche/Genentech, Novartis and Bristol-Myers Squibb. Competition, however, is rapidly growing as more companies and products are entering this market. Analysis of the clinical pipeline indicates that 142 companies are currently developing targeted cancer therapies.

Strong Pfizer pipeline